15th INTERNATIONAL CONGRESS OF PARKINSON'S

More documents

Recommendations

Info

Daily Schedule 34 Session Definitions Blue Ribbon Session: This session will provide a critical review of the best poster presentations by a panel of experts, highlighting the relevance, novelty and quality of both clinical and basic research presented by the delegates. Controversies: This Plenary Session is designed to involve all International Congress attendees. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists. Corporate Therapeutic Sessions: These company-based informational sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics. Guided Poster Tours: Guided Poster Tours will give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories. Parallel Sessions: These concurrent sessions provide an in-depth report of the latest research findings, state-of-the-art treatment options, as well as a discussion of future strategies. Parallel sessions will have evidence-based components and incorporate the “hot” issues in Parkinson’s disease and other movement disorders. Plenary Sessions: These sessions provide a broad overview of the latest clinical and basic science research findings and state-of-the-art information. Poster Sessions: Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Authors will be present for two hours each day to explain their work and answer questions. Scientific Discussions: These interactive sessions focusing on an important set of scientific questions will bring two world experts together for a dialog that will also incorporate discussion from the participants. Like Video and Skills Workshops, these are designed without formal talks, but are meant to share with the audience the equipose of important laboratory or scientific issues and the approaches that experts are using to reach answers. Skills Workshops: These clinic-based training sessions provide an educational illustration of clinical techniques and treatment procedures through demonstrations utilizing patient videotapes and proper equipment to further develop practitioners’ skills and knowledge within the field of treatment of movement disorders. Teaching Courses: These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides. In addition, these programs provide ample time for questions and a discussion period at the conclusion of the presentations. Therapeutic Plenary Sessions: These sessions provide the latest information regarding the scientific and clinical evidence supporting treatment options for Parkinson’s disease and other movement disorders. Video Sessions: Designed to provide a broad overview of related movement disorders, the video sessions will focus on the phenomenology covering the many different kinds of movement disorders affecting the population today. TICKET = Ticket required for entry. Please check the Registration Desk for ticket availability. There is no extra charge for session tickets. Special Meeting Theme: Behavioral and motor interfaces of movement disorders: From laboratory to patient care At each annual International Congress, the Congress Scientific Program Com mittee selects a theme that is highlighted throughout the meeting. This year’s theme, “Behavioral and motor interfaces of movement disorders: From laboratory to patient care,” will be showcased on two Plenary Sessions, six Parallel Sessions, one Skills Workshop, one Teaching Course, and two Video Sessions. International experts will serve as faculty, and the presentations will run the gamut of the field, from new research to practical ap plications. Meeting participants can elect to attend any or all of the sessions. These sessions are designated with a The Movement Disorder Society .
Sunday, June 5, 2011 1105 Therapeutic Plenary Session I Evidence based medicine and practice parameters: How to treat Mr. Jones 8:00 – 10:00 Location: South Building, Level 800, Hall FG Chairs: Cristina Sampaio Lisbon, Portugal William Weiner Baltimore, MD, USA 8:00 The principles of evidence based medicine and the Cochrane collaboration: How to use evidence to treat an individual patient Cristina Sampaio Lisbon, Portugal 8:40 An update from the MDS EBM Task Force 2011: Review of treatments for movement disorders Shen-Yang Lim Kuala Lumpur, Malaysia 9:20 Practice parameters in movement disorders: Principles and an update for 2011 Theresa Zesiewicz Tampa, FL, USA At the conclusion of this session, participants should be better able to: 1. Understand the differences between Evidence Based Medicine (EBM) and Practice Parameters 2. Discuss the latest EBM reviews of treatments for movement disorders 3. Review the latest Practice Parameters as related to management of movement disorders Recommended Audience: Basic Scientists; Clinical Academicians; Practitioners; Non-Physician Health Professionals; Students/Residents/Trainees 1106 Therapeutic Plenary Session II Parkinson’s disease therapy for the advanced patient: What are the options when conventional treatments have failed? 10:30 – 12:30 Location: South Building, Level 800, Hall FG Chairs: Angelo Antonini Venice, Italy K. Ray Chaudhuri London, United Kingdom 10:30 The preclinical evidence supporting continuous drug delivery in patients with advanced Parkinson’s disease M. Maral Mouradian Piscataway, NJ, USA 15 th INTERNATIONAL CONGRESS OF PARKINSON’S DISEASE AND MOVEMENT DISORDERS 1106 Therapeutic Plenary Session II continued 11:10 Comparative effects on motor symptoms with advanced therapies, including LCIG, Apomorphine or Deep Brain Stimulation Carl Clarke Birmingham, United Kingdom 11:50 Effects on non-motor symptoms and quality of life with advanced Parkinson’s disease therapies Lisa Shulman Baltimore, MD, USA At the conclusion of this session, participants should be better able to: 1. Understand the rationale supporting the use of continuous drug delivery strategies in patients with advanced Parkinson’s disease 2. Identify the technical challenges and side effects with these therapy options and how the choice of therapy can be made in a rational way 3. Describe the motor, non-motor and health related quality of life effects of treatments with Levodopa- Carbidopa Intestinal Gel (LCIG), apomorphine and Deep Brain Stimulation Recommended Audience: Basic Scientists; Clinical Academicians; Practitioners; Non-Physician Health Professionals; Students/Residents/Trainees Supported by an unrestricted educational grant from Impax Pharmaceuticals. 1107 Therapeutic Plenary Session III Deep Brain Stimulation: New developments 14:00 – 16:00 Location: South Building, Level 800, Hall FG Chairs: Joachim Krauss Hannover, Germany Andres Lozano Toronto, ON, Canada 14:00 New technology: Hardware and stimulation algorithms Peter Tass Jülich, Germany 14:40 Multiple target strategies Joachim Krauss Hannover, Germany 15:20 MR imaging: Preoperative and postoperative issues Philip Starr San Francisco, CA, USA At the conclusion of this session, participants should be better able to: 1. Identify new technology developments and programming options in Deep Brain Stimulation 2. Discuss indications and techniques to approach multiple targets 35 Daily Schedule Sunday
Page 2 and 3: Claiming CME Credit To claim CME cr
Page 4 and 5: 2 Welcome Dear Colleagues and Frien
Page 6 and 7: About MDS 4 About MDS The Movement
Page 8 and 9: About MDS 6 About MDS Congress Loca
Page 10 and 11: MDS About Education MDS 8 Education
Page 12 and 13: MDS About Education MDS 10 Educatio
Page 14 and 15: MDS About Education MDS 12 Audio-Vi
Page 16 and 17: Membership About MDS 14 Connect wit
Page 18 and 19: Toronto Information About MDS 16 Do
Page 20 and 21: Toronto Information About MDS 18 To
Page 22 and 23: International Congress Information
Page 38 and 39: Daily Schedule Sunday Sunday and Mo
Page 40 and 41: Daily Schedule Monday 38 Monday, Ju
Page 42 and 43: Daily Schedule Monday 40 Monday, Ju
Page 44 and 45: Daily Schedule Monday and Tuesday t
Page 46 and 47: Daily Schedule Tuesday 44 Tuesday,
Page 48 and 49: Daily Schedule Tuesday 46 Tuesday,
Page 50 and 51: Daily Schedule Wednesday 48 Wednesd
Page 52 and 53: Daily Schedule Wednesday 50 Wednesd
Page 54 and 55: Daily Schedule Thursday 52 Wednesda
Page 56 and 57: Daily Schedule Thursday 54 Thursday
Page 58 and 59: Daily Schedule Thursday 56 Thursday
Page 60 and 61: Faculty Listing 58 Faculty Listing
Page 62 and 63: Faculty Listing 60 Faculty Listing
Page 64 and 65: Corporate Faculty Therapeutic Listi
Page 66 and 67: Leading Advances in DBS Patient Man
Page 68 and 69: This therapy is not for everyone. D
Page 70 and 71: Exhibits 68 Exhibitor Directory ABB
Page 72 and 73: Exhibits 70 Exhibitor Directory GE
Page 74 and 75: Exhibits 72 Exhibitor Directory MER
Page 76 and 77: Exhibits 74 Exhibitor Directory TEV
Page 78 and 79: Exhibits 76 Exhibitor Floor Plan
Page 80 and 81: Guided Poster Tours 78 Guided Poste
Page 86 and 87:
Guided Poster Tours 84 Guided Poste
Page 88 and 89:
Abstracts by topic 86 Abstracts by
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 131 and 132:
DBS | Advance A New Day in DBS The
show all

15th INTERNATIONAL CONGRESS OF PARKINSON'S

Create successful ePaper yourself

Delete template?

Save as template?